Wednesday, January 27, 2016 5:44:00 AM PDT | VentureDeal
Vista, California -- Biotechnology company Exagen Diagnostics has received $16.8 million in new equity venture capital, according to an SEC regulatory filing.
Exagen is working on commercializing small sets of genomic markers to provide prognostic reagents for commercial laboratory testing and for pharmaceutical use in clinical trials. Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds. A total of 13 investors participated in the offering. Exagen is still seeking $14 million in additional financing, according to the filing.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
